Children in whom the spare adrenaline device can be used

Adrenaline devices (ADs) are used in the emergency management of anaphylaxis, and can buy valuable time while waiting for an ambulance to arrive.

Under existing legislation, teachers and other non-healthcare professionals may administer an adrenaline device, but only to a person prescribed that device, using the device prescribed to them. In other words, they cannot use an AD belonging to child ‘A’ to treat anaphylaxis occurring in child ‘B’.

The Human Medicines (Amendment) Regulations 2017 allowed schools to obtain (without a prescription) “spare” AAI devices, for use in emergencies. From September 2026, under the Allergy safety in schools statutory guidance, there is an expectation that schools should hold “spare” AAIs. This will become a legal requirement in 2027, through regulations being introduced under the Children’s Wellbeing and Schools Act 2026.

“Spare” AAI devices can be used in any pupil known to be at risk of anaphylaxis, so long as the school have medical approval for the “spare” AAI to be used in a specific pupil, and the child’s parent/guardian has provided written authorisation.

Not all children with food allergies and at risk of anaphylaxis are prescribed AAIs. These children can still be given a spare AAI in an anaphylaxis emergency.

Under the Human Medicines (Amendment) Regulations 2017, in an emergency which could not be foreseen, written consent is not required for “spare” adrenaline devices to be used. This includes the “spare” device being used in anyone (including adult visitors) having anaphylaxis on school premises.

Therefore, if someone on school premises may be having anaphylaxis:

  • If the child, young person or individual has their own prescribed adrenaline devices, these should be used in the first instance.
  • If the child, young person or individual does not have prescribed adrenaline devices, “spare” adrenaline devices can be used.
  • If the child, young person or individual’s prescribed adrenaline devices are not available or misfire, “spare” adrenaline devices can be used.

To use a “spare” adrenaline device in a pupil known to be at risk of anaphylaxis, the school must have written approval from both the pupil’s healthcare professional and parent/guardian. Unless medical authorisation and parent/guardian consent have been provided, schools cannot administer the adrenaline device to a pupil having anaphylaxis except in an absolute emergency.

The British Society for Allergy and Clinical Immunology (BSACI) has produced a range of Allergy Action Plans, which can be used for this purpose, as part of the pupil’s individual healthcare plan. Almost all Children’s Allergy clinics in the UK now use the BSACI plans to their patients. The plans can be downloaded here.

Schools don’t have to use the BSACI plans, but then they need to have an alternative in place which includes information on:

  • Known allergens and risk factors for anaphylaxis in the pupil.
  • Whether the pupil has been prescribed an adrenaline device (and if so what type and dose).
  • Whether parental consent has been given for use of the spare adrenaline device.
  • A photograph of the pupil to allow a visual check to be made (this will require parental consent).

These details should also be kept in a register in school. Schools need to ensure they have a proportionate and flexible approach to checking the register. Delays in giving adrenaline have been associated with fatal outcomes. Allowing pupils to keep their adrenaline device(s) with them will reduce delays, and allows for confirmation of consent without the need to check the register.

Similarly, it is good practice for the school, college or setting to obtain advance consent from parents or the young person for “spare” adrenaline devices to be used, so that in an emergency, consent can be assumed to be in place.

It is up to individual schools to decide when it is best to obtain parental/guardian consent for use of an adrenaline device. The most appropriate time is probably when a pupil’s individual healthcare plan is agreed. Consent should be updated regularly – ideally annually – to take account of any changes.

To help us understand who uses this website please could you tell us whether you are a:

User Type(Required)